About Prothena Corporation plc - Ordinary Shares (PRTA)
Prothena Corp is a biotechnology company focused on the discovery and development of innovative therapies to treat diseases caused by protein misfolding and aggregation. The company specializes in the research and development of monoclonal antibodies and other advanced treatments aimed at targeting neurodegenerative diseases, including Alzheimer's and Parkinson's. Through its proprietary platform, Prothena aims to address significant unmet medical needs by advancing its drug candidates through clinical trials, ultimately seeking to enhance the quality of life for patients suffering from these challenging conditions. Read More
Wondering how the US markets performed in the middle of the day on Tuesday? Discover the movers and shakers of today's session in our comprehensive analysis.
As the regular session of the US market on Monday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Prothena Corporation plc (NASDAQ:PRTA) today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint (HR=0.915, p-value=0.7680). Based on these results, the Company will discontinue the development of birtamimab, including stopping the open label extension of the AFFIRM-AL clinical trial.
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported financial results for the first quarter of 2025 and provided business highlights.
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025, after the close of the U.S. financial markets.
